Predictors of Pulmonary Zygomycosis versus Invasive Pulmonary Aspergillosis in Patients with Cancer | Zendy

George Chamilos | Zendy; Edith M. Marom | Zendy; Russell E. Lewis | Zendy; Michail S. Lionakis | Zendy; Dimitrios P. Kontoyiannis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Predictors of Pulmonary Zygomycosis versus Invasive Pulmonary Aspergillosis in Patients with Cancer

Author(s) -

George Chamilos,

Edith M. Marom,

Russell E. Lewis,

Michail S. Lionakis,

Dimitrios P. Kontoyiannis

Publication year - 2005

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/430710

Subject(s) - zygomycosis , medicine , pulmonary aspergillosis , aspergillosis , mycosis , antifungal , amphotericin b , cancer , aspergillus , dermatology , intensive care medicine , surgery , immunology , microbiology and biotechnology , biology

Pulmonary zygomycosis (PZ), an emerging mycosis among patients with cancer, has a clinical manifestation similar to that of invasive pulmonary aspergillosis (IPA). Most cases of PZ in such patients develop as breakthrough infections if treatment with antifungal agents effective against Aspergillus species is administered. However, clinical criteria to differentiate PZ from IPA are lacking.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research